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1. Introduction 
Osteoporosis is a worldwide major public health problem. Bone densitometry has become 
the “gold standard” in its diagnosis and treatment evaluation(El Maghraoui and Roux 2008). 
With its advantages of high precision, short scan times, low radiation dose, and stable 
calibration, dual-energy x-ray absorptiometry (DXA) has been established by the World 
Health Organization (WHO) as the technique of reference for assessing bone mineral 
density (BMD) in postmenopausal women and based the definitions of osteopenia and 
osteoporosis on its results. Recently, efficient therapeutic options for treatment of 
osteoporosis have been developed which create possibilities of effective intervention. 
Therefore, screening for and treatment of osteoporosis are widely practised in 
postmenopausal women and in people with an increased risk of osteoporosis because of 
underlying diseases (e.g. chronic rheumatic diseases especially when treated by 
corticosteroids)(Phillipov, Seaborn et al. 2001). Moreover, BMD measurement is needed to 
select patients for osteoporosis treatment, as there is no proof that drugs for osteoporosis 
(other than hormone replacement therapy [HRT]) are beneficial in women with clinical risk 
factors for fractures but normal BMD values.  
It has also become more and more common to perform a second DXA measurement to 
monitor BMD status or the effect of therapeutic intervention. When a second measurement 
is performed on a patient, the clinician needs to distinguish between a true change in BMD 
and a random fluctuation related to variability in the measurement procedure. The 
reproducibility of DXA measurements is claimed to be good. Such variability is due to 
multiple causes, such as device errors, technician variability, patients’ movements, and 
variation due to other unpredictable sources (Nguyen, Sambrook et al. 1997; Lodder, Lems 
et al. 2004).  
The precision error is usually expressed as the coefficient of variation (CV), which is the 
ratio of the standard deviation (SD) to the mean of the measurements, although several other 
statistics to express reproducibility exist such as the smallest detectable difference (SDD) or 
the least significant change (LSC). The SDD represents a cut-off that can be measured in an 
individual and is usually considered more useful than the CV in clinical practice (Fuleihan, 
Testa et al. 1995; Ravaud, Reny et al. 1999).  
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2. Methods of bone mineral density reproducibility measurement 
Precision errors are evaluated by performing repeated scans on a representative set of 
individuals to characterize the reproducibility of the technique. Most published studies 
examine the short-term precision error, based on repeated measurements of each subject 
performed over a time period of no more than 2 weeks. Over such a short period, no true 
change in BMD is expected. 
2.1 The coefficient of variation (CV) 
The CV, the most commonly presented measure for BMD variability, is the SD corrected for 
the mean of paired measurements. CV, expressed as a percentage, is calculated as CV (%) = 
(√((∑(a-b)2)/2n))/((Ma+Mb)/2)x100 where a and b are the first and the second measurement, 
Ma and Mb are the mean values for the two groups, and n is the number of paired 
observations.  
Reproducibility is far better for BMD measurement than for most laboratory tests. 
Reproducibility expressed by the CV is usually 1–2% at the spine on anteroposterior images 
and 2–3% at the proximal femur in individuals with normal BMD values; the difference 
between the two sites is ascribable to greater difficulties with repositioning and examining the 
femur, as compared to the spine. However, these data obtained under nearly experimental 
conditions may not apply to everyday clinical practice. Reproducibility depends heavily on 
quality assurance factors, including tests to control the quality and performance of the 
machine, as well as the experience of the operator. Assessment of machine performance 
requires daily scanning of a phantom (which may be anthropomorphic or not), followed by 
calculation of the in vitro coefficient of variation (CV), which serves to evaluate short-term and 
longterm performance and to detect drift in measurement accuracy. These in vitro data, 
however, do not necessarily reflect in vivo reproducibility, which should be evaluated at each 
measurement centre. Measurements are obtained either three times in each of 15 patients or 
twice in each of 30 patients, and the CV (m/r) is calculated from the mean (m) and standard 
deviation (r) of these repeated measurements. The CV is expressed as a percentage and 
depends on mean BMD values(Phillipov, Seaborn et al. 2001). The standard deviation reflects 
measurement error, which is a characteristic of machine performance and is independent from 
the value measured.  
2.2 The least significant change (LSC) 
For two point measurements in time, a BMD change exceeding 2√2 times the precision error 
(PE) of a technique is considered a significant change (with 95% confidence): the 
corresponding change criterion has been termed "least significant change" or LSC. LSC = 2.8 
x PE; where PE is the largest precision error of the technique used (or more easily the CV 
expressed in percentage). This smallest change that is considered statistically significant is 
also expressed in percentage(Gluer 1999).  
2.3 The smallest detectable difference (SDD) 
The measurement error can be calculated using Bland and Altman’s 95% limits of agreement 
method(Bland and Altman 1986). Precision expressed by this method gives an absolute and 
metric estimate of random measurement error, also called SDD. In this case, where there are 
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two observations for each subject, the standard deviation of the differences (SDdiff) estimates 
the within variability of the measurements. Most disagreements between measurements are 
expected to be between limits called ‘‘limits of agreement’’ defined as dz(1-a/2) SDdiff where 
d is the mean difference between the pairs of measurements and z(1-a/2) is the 100(1-a/2)th 
centile of the normal distribution. The value d is an estimate of the mean systematic bias of 
measurement 1 to measurement 2. d is expected to be 0 because a true change in BMD is not 
assumed to occur during the interval between the two BMD measurements. Defining a to be 
5%, the limits of agreement are +1.96SDdiff and -1.96SDdiff. Thus, about twice the standard 
deviation (SD) of the difference scores gives the 95% limits of agreement for the two 
measurements by the machine. A test is considered to be capable of detecting a difference, in 
absolute units, of at least the magnitude of the limits of agreement.  
3. Clinical implications of bone mineral density reproducibility measurement 
In clinical practice, two absolute values (g/cm2) have to be compared, rather than two 
percentages (T-scores). When serial measurements are obtained in a patient, only changes 
greater than the LSC (in %) or the SDD (in g/cm2) can be ascribed to treatment effects. 
Smaller changes may be related to measurement error. 
We studied recently the in vivo short term variability of BMD measurement by DXA in 
three groups of subjects with a wide range of BMD values: healthy young volunteers, 
postmenopausal women and patients with chronic rheumatic diseases (most of them taking 
corticosteroids). In all studied subjects, reproducibility expressed by different means was 
good and independent from clinical and BMD status. Thus, the clinician interpreting a 
repeated DXA scan of a subject should be aware that a BMD change exceeding the LSC is 
significant, in our centre arising from a BMD change of at least 3.56% at the total hip and 
5.60% at the spine. Expressed as SDD, a BMD change should exceed 0.02 g/cm2 at the total 
hip and 0.04 g/cm2 at the spine before it can be considered a significant change(El 
Maghraoui, Do Santos Zounon et al. 2005). Indeed, it has become usual to perform repeated 
DXA measurement: in postmenopausal women to monitor efficacy of treatment and in 
patients with chronic rheumatic diseases where high prevalence of bone loss has been 
demonstrated (Maillefert, Aho et al. 2001; Johnson, Petkov et al. 2005) especially when long 
term corticosteroid therapy is used. In the reports published, variability is usually expressed 
as CV and the figures for short term variability are lower than the ones we found [7-9]. 
However, two studies showed variability data more in line with our results. In Ravaud et 
al.(Ravaud, Reny et al. 1999) study, two samples of healthy (n=70) and elderly (n=57) 
postmenopausal women showed a CV (%) of 0.9 and 1.8, respectively, at the spine, and of 
0.9 and 2.3, respectively, at the total hip. Eastell showed an LSC (%) of 5.4 at the lumbar 
spine and 8 at the total hip, respectively, in osteoporotic postmenopausal women (Eastell 
1996). It has been suggested that the varying results of reproducibility studies might be 
explained by the ‘‘population’’ investigated; a phantom and healthy young subjects are 
likely to show more favourable variability than postmenopausal women, possibly in part 
because of easier positioning for measurement(Gluer, Blake et al. 1995). However, our study 
failed to show better variability, expressed as CV (%), in young healthy volunteers (El 
Maghraoui, Do Santos Zounon et al. 2005). Another reason advocated was that osteoarthritis 
in postmenopausal women may contribute to poorer variability than found in healthy 
young subjects. The SDD values found in our study were comparable to the figures 
presented by Ravaud et al. (Ravaud, Reny et al. 1999). In the first group of postmenopausal 
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women (mean age 53 years) they describe, the SDD was 0.02 (g/cm2) at the total hip and 
0.02 at the lumbar spine. In the second group described, women with a mean age of 80 
years, these figures were 0.04 and 0.04, respectively. In Lodder et al.(Lodder, Lems et al. 
2004)  study (Ninety five women, mean age 59.9 years), the SDD was 0.04 (g/cm2) at the 
total hip and 0.05 at the lumbar spine. The SDD values of the children studied in this study 
tended to be lower than the values in the postmenopausal women (table I). Using the SDD, 
one can state that a (BMD) change larger than the figure found is a true (BMD) change in 
95% of the cases. The characteristics of the Bland and Altman method thus allow direct 
insight into the variability of the measurement under study (figure 1).  
It has been shown that reproducibility expressed using the SDD is independent of the BMD 
value whereas reproducibility expressed using the CV or the derived LSC depend on the 
BMD value. Ravaud et al.(Ravaud, Reny et al. 1999) reported that using SD, the values of the 
cut-offs are 0.024, 0.030, 0.020, and 0.021 g/cm2 for postmenopausal women aged 70 years 
and 0.040, 0.033, 0.033, and 0.038 g/cm2 for postmenopausal osteoporotic women aged >70 
years at the spine, femoral neck, greater trochanter, and total hip, respectively. Using CV, 
cut-offs vary depending on the BMD level. In postmenopausal women aged >70 years, for a 
BMD level between 0.600 g/cm2 and 1.000 g/cm2, the cut-offs derived from CV vary 
between 0.015 g/cm2 and 0.024 g/cm2, 0.024 g/cm2 and 0.041 g/cm2, 0.018 g/cm2 and 0.030 
g/cm2, 0.015 g/cm2 and 0.025 g/cm2 for the spine femoral neck, greater trochanter, and total 
hip, respectively. In postmenopausal osteoporotic women aged >70 years, for the same 
range of BMD level, cut-offs vary between 0.031 g/cm2 and 0.051 g/cm2, 0.038 g/cm2 and 
0.063 g/cm2, 0.043 g/cm2 and 0.071 g/cm2, 0.038 g/cm2 and 0.063 g/cm2 for the same bone 
sites. Consequently, to express variability on a percentage basis using CV leads to 
underestimate variability in patients with low BMD and to overestimate variability in 
patients with high BMD. Previous reports in the literature, as well as Ravaud, Lodder’s data 
and our data (table 1) demonstrate that absolute precision errors derived from SD are 
constant across a wide range of BMD values and independent of the level of BMD. Because 
of therapeutic consequences, the clinician should be especially careful in judging an 
apparent BMD change in patients with osteoporosis. Influence of age on BMD 
reproducibility is controversial. Previous studies have suggested that BMD measurement 
errors were independent of age even some studies suggested that SDD may vary in extreme 
ages (children and elderly) probably because of age-related factors other than BMD. 
However, a few data exist for reproducibility of DXA in women over 70. Ravaud et al. data, 
as well as those of Fuleihan (Fuleihan, Testa et al. 1995), and Maggio et al. (Maggio, 
McCloskey et al. 1998) show that the measurement error is greater in older osteoporotic 
subjects. Several factors such as difficulties in repositioning could explain the increase of 
measurement error in this kind of patients. Therefore, the use of the SDD in the evaluation 
of an apparent BMD change gives a more conservative approach than the use of the CV at 
low BMD. Because of its independence from the BMD level and its expression in absolute 
units, the SDD is a preferable measure for use in daily clinical practice as compared with the 
CV and the derived LSC.  
In contrast with all previous publications about DXA reproducibility, we found in our 
centre better results for the hip BMD variability than the lumbar spine. This is due to the fact 
that our study was the first to use the mean measure of the two femurs (dual femur). In this 
study, we showed in a group of young healthy volunteers that the SDD was ±0.0218 g/cm2 
when both femurs were measured whereas it was ±0.0339 g/cm2 when only one femur was 
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measured. Thus, these results enhance to encourage the use of the measurement of both hips 





Fig. 1. Graph of the difference score against the mean score of the total hip (a) and the 
lumbar spine (b) BMD measurements (g/cm2) in our centre [17] using Bland and Altman 













































Mean difference, mean of the difference between the first and the second BMD measurement; SD difference, SD o
and the second BMD measurement; SDD, smallest detectable difference (g/cm2); CV, coefficient of variation (%); 
ICC, intraclass correlation coefficient.  
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Although the variability as expressed by the CV, and especially the SDD, is reassuring, 
showing good short term variability at group level, the wide range of the differences in 
BMD and the derived T-scores indicates considerable individual differences between two 
consecutive BMD measurements in some patients. The range in ΔT scores, for example, 
indicates that in some patients the diagnosis, based on the diagnostic thresholds of the 
WHO, would change owing to the measurement variability.  
In summary, reproducibility of BMD measurement by DXA in different kinds of patients 
(postmenopausal women, patients with chronic rheumatic diseases, elderly…) expressed by 
different means is good at a group level. However, the clinician must remain aware that an 
apparent BMD change in an individual patient may represent a precision error. At each 
measurement centre, the SDD should be calculated from in vivo reproducibility data. In 
clinical practice, the SDD should be used to estimate the significance of observed changes, in 
absolute values.  
5. Other factors influencing DXA monitoring 
The first factor is the time interval between two measurements in the same patient which 
must be long enough to allow occurrence of a change greater than the SDD or the LSC. 
Therefore, it depends on the expected rate of change in BMD measurement (which varies 
according to whether the measurement site is composed predominantly of trabecular or of 
cortical bone) and the reproducibility of BMD measurement at that site. Thus, in clinical 
practice, a treatment-induced BMD increase can only be detected in general after 2 years. 
However, in patients receiving long term steroid therapy, the changes in BMD may be so 
important that they can be detected at 1 year. Thus, although the spine may not be the best 
site for the diagnosis of osteoporosis given the high prevalence of spinal degenerative 
disease, it is the most sensitive site for detecting changes over time. However, our study 
showed that measurement of both femurs (called “dual femur” in Lunar machines) 
increases the reproducibility at this site.  
In another side, the changes in BMD measurements are influenced by the ability of 
osteoporosis treatments to increase the BMD at the different skeletal sites. For some 
treatments such as teriparatide and the more potent bisphosphonates, statistically 
significant changes in spine BMD occur on time scales of 1 to 2 years in the majority of 
patients, although for other treatments, such as raloxifene, the changes are often not large 
enough to be statistically significant. Recently, the strontium ranelate trials show BMD 
increases at the spine and hip 2-5 times larger than those for BPs and SERMs, and 
comparable or greater than with teriparatide. However, it is important to appreciate that 
much of this effect is due to the higher atomic number of strontium compared with calcium. 
Thus, strontium in bone attenuates X-rays much more strongly than calcium, and BMD is 
overestimated compared with the true mass of bone mineral present. This effect may persist 
for many years after the patient stops treatment and may affect the relationship between 
BMD and fracture risk. 
Thus, treatment dosages cannot be adjusted on the basis of BMD changes. Moreover, there is 
no proof that repeating BMD measurements improves compliance, as most patients 
discontinue antiresorptive medications after a few months because of administration 
constraints, side effects, cost of medications or lack of interest.  
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Above all, BMD is used as a surrogate marker for the fracture risk, yet BMD increases do not 
reliably reflect a reduction in the fracture risk. Although bisphosphonates, raloxifene, and 
strontium have not been compared in the same study, they seem to produce comparable 
reductions in the risk of vertebral fractures, of about 30–50%, whereas BMD changes differ 
markedly across medications. Studies have shown that BMD gains explain only a small 
proportion of the vertebral fracture risk reduction: 28% with risedronate(Li, Meredith et al. 
2001), 16% with alendronate(Cummings, Karpf et al. 2002), and 4% with raloxifene(Sarkar, 
Mitlak et al. 2002). It has been suggested that the percentage of BMD change may be related 
to the change in the relative risk of fracture(Wasnich and Miller 2000). In one study, a linear 
relationship was found between these two parameters, but a 1% increase in spinal BMD was 
associated with an only 3% decrease in the relative risk of vertebral fracture(Cummings, 
Karpf et al. 2002). For peripheral fractures, in contrast, the risk reduction is clearly related to 
the BMD gain(Hochberg, Greenspan et al. 2002). Common sense indicates that a BMD 
increase during treatment should be preferable over a BMD decrease. However, data 
showing that the fracture risk may decrease despite a reduction in BMD have been reported 
(Watts, Geusens et al. 2005). It has also been shown that the fracture risk was more heavily 
dependent on BMD at baseline than on BMD changes during treatment (Hochberg, Ross et 
al. 1999).  
6. Conclusion 
Serial BMD measurements can be used to monitor current antiresorptive treatments 
(raloxifene, bisphosphonates or strontium ranelate). However, adequate quality-control 
procedures must be used(Roux, Garnero et al. 2005). Measurement error must be considered 
when evaluating serial assessments. A clear understanding of the interpretation of serial 
measurements and the statistical principles impacting upon their interpretation is necessary 
to determine whether a change is real and not simply random fluctuation. It is inadequate to 
simply use the manufacturer’s default precision error, which may underestimate the 
precision error in the clinical setting. Thus, every centre should calculate its own precision 
error from in vivo reproducibility data. International societies interested in osteoporosis 
diagnosis and management such as the International Society for Clinical Densitometry or 
the International Osteoporosis Foundation should add to their guidelines at least two 
recommendations about DXA monitoring highlighted in this paper: the measurement of 
both hips improves the reproducibility at this site and DXA measurement centres should 
determine and use the individual SDD.  Indeed, the use of the SDD is preferable to the use of 
the CV and LSC because of its independence from BMD level and its expression in absolute 
units. The exact definition and advices for the measure and use of these parameters in 
clinical practice should be clearly explained. It is clear that the choice of the optimum site for 
performing follow-up scans depends on the ratio of the BMD treatment effect to the 
precision of the measurements. The larger this ratio, the more statistically significant the 
observed changes are likely to be. Actually, all data agree in showing that the spine is the 
optimum site. In clinical practice, BMD measurements have to be spaced at least 2 years 
apart. The main goal of serial BMD measurement is to check that no further bone loss has 
occurred; estimation of BMD gains is the secondary objective. This should be explained to 
the patients, many of whom expect to recover normal BMD values.  
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